Kolexia
Laki Fatima Gynécologie
Laki Fatima
Gynécologie
Clcc Institut Curie
Paris, France
48 Activités
203 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du sein Tumeurs du sein triple-négatives Récidive tumorale locale Carcinomes Métastase lymphatique Cancers du sein inflammatoires Maladie résiduelle Carcinome canalaire du sein Dermatite

Collaborateurs

Voir plus
Kirov Youlia
Kirov Youlia
Clcc Institut Curie, Paris, France
Fourquet Alain
Fourquet Alain
Clcc Institut Curie, Paris, France
Loap Pierre
Loap Pierre
Clcc Institut Curie, Paris, France
Pierga Jean-Yves
Pierga Jean-Yves
Clcc Institut Curie, Paris, France

Industries

Voir plus
{{person.topindus1.name}}
{{person.topindus1.tot}} collaboration(s)
Dernière en {{person.topindus1.last}}
{{person.topindus2.name}}
{{person.topindus2.tot}} collaboration(s)
Dernière en {{person.topindus2.last}}
{{person.topindus3.name}}
{{person.topindus3.tot}} collaboration(s)
Dernière en {{person.topindus3.last}}
{{person.topindus4.name}}
{{person.topindus4.tot}} collaboration(s)
Dernière en {{person.topindus4.last}}

Dernières activités

Voir plus
RadioPARP: A Phase I of Olaparib With Radiation Therapy in Patients With Inflammatory, Loco-regionally Advanced or Metastatic TNBC (Triple Negative Breast Cancer) or Patient With Operated TNBC With Residual Disease
Essai Clinique (AstraZeneca)   29 janvier 2024
Outcomes and toxicity of concurrent CDK4/6 inhibitor and locoregional radiotherapy for patients with de novo metastatic breast cancer.
International journal of cancer   28 juin 2023
Long-term efficacy and tolerance of a technique for postmastectomy electron beam radiation therapy of the unreconstructed chest wall and lymph node areas for non-metastatic breast cancers.
Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique   09 mai 2023
Concurrent Olaparib and Radiotherapy in Patients With Triple-Negative Breast Cancer: The Phase 1 Olaparib and Radiation Therapy for Triple-Negative Breast Cancer Trial.
JAMA oncology   19 décembre 2022
Concurrent Olaparib with Radiotherapy in Patients with Triple Negative Breast Cancer: Final Results of the RADIOPARP Phase 1 Trial
ASTRO Annual 2022 Meeting   01 novembre 2022
How to improve the surgical trials quality in daily practice.
Bulletin du cancer   19 août 2022
Safety and tolerability of olaparib combined with breast radiotherapy in patients with triple-negative breast cancer: Final results of the RADIOPARP phase 1 trial.
2022 ASCO Annual Meeting I   02 juin 2022
Clinical outcomes of curative-intent multimodal management of chemorefractory nonmetastatic inflammatory breast cancer.
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]   01 juin 2022
Breast Magnetic Resonance Image Analysis for Surgeons Using Virtual Reality: A Comparative Study.
JCO clinical cancer informatics   29 avril 2022
The place of the boost in the breast cancer treatment: State of art.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology   17 mars 2022